AbbVie Inc (ABBV) : Lourd Capital scooped up 229 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 6,375 shares of AbbVie Inc which is valued at $424,384.AbbVie Inc makes up approximately 0.12% of Lourd Capital’s portfolio.
Other Hedge Funds, Including , Integrated Wealth Management boosted its stake in ABBV in the latest quarter, The investment management firm added 276 additional shares and now holds a total of 28,670 shares of AbbVie Inc which is valued at $1,908,562. AbbVie Inc makes up approx 0.73% of Integrated Wealth Management’s portfolio. Inr Advisory Services added ABBV to its portfolio by purchasing 1,197 company shares during the most recent quarter which is valued at $79,277. AbbVie Inc makes up approx 0.01% of Inr Advisory Services’s portfolio.Duff Phelps Investment Management Co reduced its stake in ABBV by selling 700 shares or 3.22% in the most recent quarter. The Hedge Fund company now holds 21,050 shares of ABBV which is valued at $1,394,142. AbbVie Inc makes up approx 0.02% of Duff Phelps Investment Management Co’s portfolio.Wagner Bowman Management Corp reduced its stake in ABBV by selling 141 shares or 0.85% in the most recent quarter. The Hedge Fund company now holds 16,402 shares of ABBV which is valued at $1,064,490. AbbVie Inc makes up approx 0.41% of Wagner Bowman Management Corp’s portfolio.Tnb Financial boosted its stake in ABBV in the latest quarter, The investment management firm added 993 additional shares and now holds a total of 29,446 shares of AbbVie Inc which is valued at $1,867,171. AbbVie Inc makes up approx 0.48% of Tnb Financial’s portfolio.
AbbVie Inc closed down -0.47 points or -0.71% at $66.1 with 49,01,851 shares getting traded on Thursday. Post opening the session at $66.58, the shares hit an intraday low of $66.08 and an intraday high of $66.98 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.